Non-muscle Invasive Bladder Cancer Therapeutics Market Size, Share and Global Trend By Stage (Carcinoma in Situ (CIS), T1 Stage, Ta Stage), By Treatment (Immunotherapy, Chemotherapy, Others), By Route of Administration (Systemic, Intravesical, Others), By Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2024-2032

In July 2018, UroGen Pharma Ltd., submitted an application for the UGN-102 (VesiGel, mitomycin gel for intravesical instillation) for the treatment of low-grade non-muscle-invasive bladder cancer to the U.S. Food and Drug Administration (FDA). Non-muscle invasive bladder cancer is also known as superficial bladder cancer. This type of bladder cancer is found on the surface of the interior lining of the bladder.

Indications include, blood in urine, passage urine frequently and torment in the pelvis. Various drugs in development and in different phases of clinical trials are anticipated to fuel the global non muscular invasive bladder cancer therapeutics market. One of the major factors leading to non muscular invasive bladder cancer is smoking.

The global non-muscle-invasive bladder cancer therapeutics market is expected to grow rapidly during the forecast period, owing to the increasing incidence and prevalence of bladder cancer, advancement in health care services, technological advancements in the bladder cancer detection system leading to the high demand in the treatment.

Also, increasing adoption of smoking, rising geriatric population, growing demand for the different effective drugs and therapeutics are anticipated to supplement the growth of the global non-muscle-invasive bladder cancer therapeutics market.

The factor that is expected to inhibit the growth of the market is the high cost associated with bladder cancer treatment combined with many side effects after the treatment which include nausea, a low-grade fever, chills, kidney damage.

Key Players Covered

Some of the major companies that are present in the global non- muscle invasive bladder cancer therapeutics market are Pfizer, Inc., GlaxoSmithKline, Celgene Corporation, Sanofi S.A, F. Hoffmann-La Roche, Novartis International AG, Eli Lilly and Co., AstraZeneca plc., Bristol-Myers Squibb and others.

SEGMENTATION

Among the types of route of administration, intravesical route of administration is estimated to dominate the global non-muscle-invasive bladder cancer therapeutics market owing to the increased efficacy of treating the disease offered by the procedure.

Key Insights

• Prevalence of Non-muscle Invasive Bladder Cancer (Key Regions)


• Pipeline Analysis


• Reimbursement Scenario (Key Regions)


• Key Mergers and Acquisitions

Regional Analysis

The global non- muscle- invasive bladder cancer therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are projected to be the two largest markets for non- muscle invasive bladder cancer therapeutics at present and they are expected to account for a large proportion of the market in the forecast period as well. This is due to the increasing prevalence of bladder cancer, the rise in geriatric population and investment in the new drug development to treat non muscle invasive bladder cancer in the region. The Asia Pacific is the expected to grow at the faster owing to rise in the number of cigarette smoking leading to the increasing prevalence of bladder cancer. Increasing awareness about the new cancer diagnosis, growing demand for the new and advanced treatment and therapies, the rise in healthcare expenditure and developing healthcare infrastructure will drive the growth of the global non-muscle-invasive bladder cancer therapeutics market in the region.

Key Industry Developments

• In December 2018, Anchiano Therapeutics, announced the initiation of Codex, the pivotal Phase 2 study of inodiftagene vixteplasmid (BC-819), a first-in-class gene therapy for patients with non-muscle-invasive bladder cancer (NMIBC).
• In May 2018, Ferring Pharmaceuticals signed agreement to commercialize nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), for the patients with high-grade non-muscle invasive bladder cancer (NMIBC), who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy.